Following years of training, he spent a decade serving a diverse base of clients at McKinsey & Company as a Partner and Co-leader in the life sciences practices, focused on strategy, diligence and forecasting. He then joined Leerink Partners as a Managing Director and Senior Analyst, providing commentary on companies focused on internal medicine – including those with interests in autoimmune disorders and metabolism. Subsequently Pasha joined Flagship Pioneering as an Operating Partner, where he led and directed a remarkable team of computational scientists and stem cell biologists who discovered novel genetic circuits in Parkinson’s Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK. Following Flagship, Dr. Sarraf joined Matterhorn Biosciences as CEO and executive board member, where he built and led a diverse team to scale and demonstrate the value of their TCR-based platform.

Pasha obtained his M.D., Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachusetts General Hospital (MGH) and National Institutes of Health (NIH), focusing on vasculitis, scleroderma and genetic inflammatory disorders. He has authored more than 50 publications and filed multiple patents for novel therapies and molecular targets.

In addition to his current leadership of Celosia, Dr. Sarraf is a board member for Cue Biopharma, PolarityBio, and Praesidia Biotherapeutics, where he also serves as Chairman.